Scottish backing for Novartis’ Afinitor for kidney cancer patients
The Scottish Medicines Consortium (SMC) has issued a positive recommendation for Swiss pharma major Novartis’ (NOVN: VX) Afinitor (everolimus) which has been accepted for use in NHS Scotland, as a treatment option for advanced kidney cancer patients who have failed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.
The positive recommendation comes at a time when there is increased focus on the SMC to approve more medicines for cancer. The SMC’s decision is long awaited news for advanced kidney cancer patients who will now have access to this treatment through NHS Scotland. This is particularly important as recent figures from the latest review of kidney cancer incidence in the UK report higher than average rates of the disease in parts of Scotland.
In contrast to negative recommendation from England’s NICE
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze